Heterogeneous reduction in pediatrics RSV hospitalizations following regional nirsevimab immunization strategies: a multicenter study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Variable Impact of Regional Nirsevimab Vaccination Strategies on RSV Hospitalizations in Pediatric Patients: A Multicenter Analysis

  • By

  • Federica Attaianese

  • Sandra Trapani

  • Ilaria Alberti

  • Maurizio Aricò

  • Marina Attanasi

  • Giulia Bertolucci

  • Silvia Bressan

  • Désirée Caselli

  • Veronica Casotto

  • Salvatore Cazzato

  • Francesco Chiarelli

  • Enrico Felici

  • Anna Frusciante

  • Maria Antonia Galeone

  • Silvia Garazzino

  • Antonietta Giannattasio

  • Eloisa Gitto

  • Antonio Guerriero

  • Fiorentina Guida

  • Giovanna Iudica

  • September 14, 2026

Share

  • 1

    RSV is the leading cause of acute lower respiratory tract infection and hospitalization among infants and young children worldwide.

  • 2

    Nirsevimab, a long-acting monoclonal antibody for RSV prevention, was approved in Europe in 2022 and first implemented in one Italian region during the 2023–2024 season.

  • 3

    Regional nirsevimab strategies in Italy differed primarily in birth month-based eligibility criteria and the timing of campaign initiation.

  • 4

    A multicenter study examined pediatric RSV-related hospitalizations across 19 Italian pediatric units from January 2019 through March 2025.

  • 5

    The study assessed early population-level changes in RSV-related hospitalizations following different regional nirsevimab implementation strategies.

Original Source(s)

Heterogeneous reduction in pediatrics RSV hospitalizations following regional nirsevimab immunization strategies: a multicenter study

  • by Federica Attaianese, Sandra Trapani, Ilaria Alberti, Maurizio Aricò, Marina Attanasi, Giulia Bertolucci, Silvia Bressan, Désirée Caselli, Veronica Casotto, Salvatore Cazzato, Francesco Chiarelli, Enrico Felici, Anna Frusciante, Maria Antonia Galeone, Silvia Garazzino, Antonietta Giannattasio, Eloisa Gitto, Antonio Guerriero, Fiorentina Guida, Giovanna Iudica

  • September 14, 2026

Related Content

Phoenix Children’s Names Mike Skafi Chief Pharmacy Officer

Phoenix Children’s today announced that Mike A. Skafi, RPh, MSQA, has been named Chief Pharmacy Officer.

  • by

  • September 16, 2026

  • 3 min
Febrile Seizures and School Performance

Diagnosis Through Whole Genome Sequencing and Care Utilization in Children With Severe Illness